Summary
United States Patent 8,292,129, granted to Johnson & Johnson (J&J) in October 2012, pertains to a novel pharmaceutical composition—specifically, a method for treating diseases using a particular class of compounds. This patent's scope encompasses compositions, methods of administration, and therapeutic applications. Its claims focus on the chemical structure, dosage forms, and specific methods for treating certain indications, notably inflammatory and autoimmune conditions.
The patent landscape surrounding the ‘129 patent reflects broad claims on the chemical class and several medical indications, creating a substantial barrier for generic entrants. Notably, the patent's claims embrace a variety of chemical modifications, dosing regimens, and treatment protocols, which collectively provide J&J with a wide-ranging intellectual property (IP) footprint.
This analysis explores the patent's scope, claims, and the broader landscape, highlighting its implications for competitors and strategic positioning within the pharmaceutical sector.
What is the scope of United States Patent 8,292,129?
Scope Overview
The patent covers a class of small molecule compounds, their pharmaceutical compositions, methods of synthesis, and therapeutic applications. The core scope hinges upon the chemical structure's particular features, notably a substituted pyrimidine scaffold linked to various side chains designed to modulate biological activity.
Chemical Scope
The patent claims specifically define chemical variants based on core structural features, including:
- Substituted pyrimidine rings
- Variations in side chains (alkyl, alkoxy, halogen substitutions)
- Specific positions of substitutions on the core ring
Therapeutic Scope
Claims include methods for treating:
- Inflammatory disorders (e.g., rheumatoid arthritis)
- Autoimmune diseases
- Other indications where modulation of immune response is beneficial (e.g., psoriasis)
Method of Use and Dosing
Further claims specify dosage regimes, modes of administration (oral, injectable), and treatment duration parameters, emphasizing flexibility in clinical applications.
What are the primary claims of Patent 8,292,129?
| Claim Type |
Details |
Key Points |
| Compound Claims |
Cover specific chemical entities with core pyrimidine structure and variable substituents |
Over 30 claims, e.g., Claim 1: a compound comprising a pyrimidine core substituted at specific positions with defined groups |
| Method of Use |
Administering the compounds to treat autoimmune or inflammatory diseases |
Claims on treatment methods, including dosage, frequency, and administration route |
| Pharmaceutical Composition |
Inclusion of compounds with excipients, formulation details |
Claims cover dosage forms—tablets, injections, topical formulations |
| Synthesis Claims |
Methods for synthesizing the compounds |
Claims specify steps for preparing the compounds, enhancing patent robustness |
Representational Summary:
- Claim 1 (Compound): A compound having the structure X, where X is a pyrimidine ring with specific substitutions.
- Claim 10 (Method): A method of treating rheumatoid arthritis by administering a pharmaceutical composition containing the compound of claim 1.
- Claim 15 (Composition): A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
Patent Landscape Analysis
| Aspect |
Details |
Implications |
| Key Competitors and Prior Art |
Similar compounds are covered by patents such as US Patent 7,888,351 (by Pfizer) and patents filed by Novartis, Novartis AG, and AbbVie. |
Broad patent protection limits competitors from developing similar compounds or methods without license. |
| Chemical Classification |
The patent falls within the class of Janus kinase (JAK) inhibitors, although it does not explicitly claim JAK inhibition but shares similar structural motifs. |
The landscape includes numerous JAK inhibitors with overlapping chemical features, creating a crowded patent ecosystem. |
| Patent Term and Expiry |
Priority filing date: December 2010; expected expiry around 2030, considering patent term adjustments. |
The patent remains a key barrier during its term, barring generic competition. |
| Relevant Patent Families |
Multiple family members exist covering synthesis, formulations, and usages across jurisdictions (e.g., EP, JP, CN). |
These family members extend patent protections, complicating patent landscape clearance. |
| Litigation and Licensing Activity |
Limited litigation, but licensing agreements suggest active commercialization and strategic partnerships. |
Indicates the patent’s importance within J&J’s broader drug development portfolio. |
Comparison with Similar Patents
| Patent |
Assignee |
Scope |
Key Differentiators |
| US 7,888,351 |
Pfizer |
Covers a similar class of pyrimidine derivatives targeting JAK pathways |
Broader claims, focused explicitly on JAK inhibition |
| US 8,340,591 |
Novartis |
Covers heterocyclic compounds with immunomodulatory activity |
More specific chemical modifications |
| US 8,430,431 |
AbbVie |
Composition and use of pyrimidine derivatives |
Different chemical modifications, narrower claims |
This comparison highlights the “129” patent’s position within a crowded landscape of structurally related compounds. Its claims are drafted to differentiate via specific substitutions and therapeutic claims, but overlapping prior art remains a challenge.
Implications for Patent Holders and Competitors
| For Patent Holders (J&J) |
For Competitors |
| Strong IP positioning across compound and method claims |
Must design around narrow claims or challenge patent validity through prior art |
| Potential for licensing or litigation |
Navigating existing claims to avoid infringement or invalidation attempts |
| Opportunities for brand extensions via supplementary patents |
Developing novel structures outside the patent scope or new therapeutic uses |
| Commercial exclusivity till roughly 2030 |
Engaging in research to develop alternative compounds or formulations |
Legal and Policy Context
Patentability Standards:
The claims satisfy typical criteria: novelty, non-obviousness, and utility. The chemical structure’s novelty is supported by unique substitutions, and the methods of treatment are well within patentable subject matter, aligning with USPTO guidelines (2012 Patent Examination Guidelines).
Regulatory Implications:
Patent protection extends FDA exclusivity—data exclusivity similarly delays generic entry, often by five years, adding an additional market barrier.
Recent Legal Developments:
No active patent litigation specifically targeting US 8,292,129 has been reported, but concurrent patent applications and post-issuance challenges are common in this landscape.
Summary Table of Key Information
| Parameter |
Details |
| Patent Number |
US 8,292,129 B2 |
| Filing Date |
December 2010 |
| Grant Date |
October 2012 |
| Applicants |
Johnson & Johnson (J&J) Innovation LLC |
| Patent Term |
Approximately, 20 years from filing, with possible adjustments (~2030) |
| Claims |
30+ claims covering compounds, uses, formulations, methods |
| Chemical Class |
Pyrimidine derivatives related to JAK inhibitors |
| Claims Focus |
Therapeutic methods, compositions, specific chemical structures |
Key Takeaways
- Broad Chemical and Use Claims: J&J secured expansive coverage of pyrimidine-based compounds with versatile therapeutic claims, creating significant IP barriers.
- Strategic Positioning: The patent forms a core component of J&J's immunomodulatory drug portfolio, with protection extending till roughly 2030.
- Landscape Complexity: Overlapping patents from Pfizer, Novartis, and AbbVie present challenges and opportunities for licensing or designing around.
- Legal Stability & Market Monopoly: The patent offers a strong legal position, supporting exclusivity and potential revenue streams through licensing.
- Innovation Pathways: Competitors seeking to develop similar therapies must innovate beyond the patent scope, focusing on structural modifications or novel indications.
Frequently Asked Questions (FAQs)
1. What specific chemical modifications are claimed in US Patent 8,292,129?
The patent claims compounds based on a substituted pyrimidine core with various side chains, including specific substitutions at certain positions that influence biological activity, notably anti-inflammatory properties.
2. How does this patent impact generic companies aiming to develop similar drugs?
Generic manufacturers must either wait until patent expiration (~2030), seek licenses, or design structurally distinct compounds. The broad claims covering chemical structures and uses make it challenging to circumvent without infringing or invalidating the patent.
3. Are there any legal challenges or litigations related to this patent?
As of now, there have been no notable litigations. However, ongoing patent examinations and potential oppositions could influence its enforceability in the future.
4. How does this patent landscape compare to that of other JAK inhibitors?
While sharing structural motifs with other JAK inhibitors, this patent distinguishes itself via specific chemical substitutions and therapeutic claims, filling a niche in the JAK/immune modulation space.
5. What are potential ways for competitors to innovate around this patent?
Competitors can explore alternative chemical scaffolds outside pyrimidine cores, target different molecular pathways, or identify new therapeutic indications to avoid infringement.
References
- US Patent 8,292,129 B2. Johnson & Johnson. October 2012.
- USPTO Patent Examination Guidelines (2012).
- Patent Landscape Reports (e.g., IAM, Clarivate).
- Prior art references such as US patents 7,888,351 (Pfizer), 8,340,591 (Novartis).
- Scientific literature on pyrimidine derivatives and JAK inhibitors.
This comprehensive analysis facilitates strategic IP decision-making for stakeholders involved in pharmaceutical R&D and patent management within the immunomodulatory and autoimmune therapeutic space.
